272 related articles for article (PubMed ID: 19966866)
1. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
[TBL] [Abstract][Full Text] [Related]
3. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin.
Malhowski AJ; Hira H; Bashiruddin S; Warburton R; Goto J; Robert B; Kwiatkowski DJ; Finlay GA
Hum Mol Genet; 2011 Apr; 20(7):1290-305. PubMed ID: 21212099
[TBL] [Abstract][Full Text] [Related]
4. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.
Kang YJ; Lu MK; Guan KL
Cell Death Differ; 2011 Jan; 18(1):133-44. PubMed ID: 20616807
[TBL] [Abstract][Full Text] [Related]
5. TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity.
Ohsawa M; Kobayashi T; Okura H; Igarashi T; Mizuguchi M; Hino O
PLoS One; 2013; 8(1):e54503. PubMed ID: 23355874
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
[TBL] [Abstract][Full Text] [Related]
8. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
[TBL] [Abstract][Full Text] [Related]
10. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
Menon S; Yecies JL; Zhang HH; Howell JJ; Nicholatos J; Harputlugil E; Bronson RT; Kwiatkowski DJ; Manning BD
Sci Signal; 2012 Mar; 5(217):ra24. PubMed ID: 22457330
[TBL] [Abstract][Full Text] [Related]
11. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.
Ozcan U; Ozcan L; Yilmaz E; Düvel K; Sahin M; Manning BD; Hotamisligil GS
Mol Cell; 2008 Mar; 29(5):541-51. PubMed ID: 18342602
[TBL] [Abstract][Full Text] [Related]
12.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
13. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Huang J; Dibble CC; Matsuzaki M; Manning BD
Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
[TBL] [Abstract][Full Text] [Related]
14. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
15. Tsc2 mutation rather than Tsc1 mutation dominantly causes a social deficit in a mouse model of tuberous sclerosis complex.
Kashii H; Kasai S; Sato A; Hagino Y; Nishito Y; Kobayashi T; Hino O; Mizuguchi M; Ikeda K
Hum Genomics; 2023 Feb; 17(1):4. PubMed ID: 36732866
[TBL] [Abstract][Full Text] [Related]
16. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
17. Cystogenesis and elongated primary cilia in Tsc1-deficient distal convoluted tubules.
Armour EA; Carson RP; Ess KC
Am J Physiol Renal Physiol; 2012 Aug; 303(4):F584-92. PubMed ID: 22674026
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
